SCHEMBL2854479

SCHEMBL2854479

O=C(Cc1c(Cl)cccc1Cl)NCc1ccc(Cl)cc1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.61
MEN1 O00255 5/20 0.61
NPC1 O15118 2/20 0.60
RAB9A P51151 2/20 0.60
ALDH1A1 P00352 2/20 0.60
HTT P42858 2/20 0.59
POLB P06746 1/20 0.58
P2RX7 Q99572 2/20 0.57
CA1 P00915 2/20 0.55
CA2 P00918 2/20 0.55
CA12 O43570 1/20 0.55
CA9 Q16790 1/20 0.55
LMNA P02545 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
ERCC1 P07992 1/20 0.54
ERCC4 Q92889 1/20 0.54
CYP2C9 P11712 1/20 0.53
CYP2C19 P33261 1/20 0.53
HPGD P15428 2/20 0.53
GAA P10253 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4037474 0.84 MEN1 (0.55) KMT2AMEN1RAB9AHTTP2RX7
SCHEMBL16082991 0.83 ALDH1A1 (0.83) KMT2AMEN1NPC1RAB9AALDH1A1
SCHEMBL7285179 0.80 ALDH1A1 (0.73) KMT2AMEN1NPC1RAB9AALDH1A1
SCHEMBL5860896 0.80 ALDH1A1 (0.73) KMT2AMEN1NPC1RAB9AALDH1A1
SCHEMBL9505080 0.77 ALDH2 (0.59) KMT2AMEN1RAB9AALDH1A1POLB
SCHEMBL7840700 0.76 MEN1 (0.58) KMT2AMEN1NPC1RAB9AALDH1A1
SCHEMBL4035227 0.75 KMT2A (0.68) KMT2AMEN1NPC1RAB9AALDH1A1
SCHEMBL10692807 0.75 KMT2A (0.68) KMT2AMEN1NPC1RAB9AALDH1A1
SCHEMBL24821237 0.75 KMT2A (0.77) KMT2AMEN1NPC1RAB9AALDH1A1
SCHEMBL4627464 0.75 SIGMAR1 (0.47) KMT2ARAB9AALDH1A1HTTCA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1451160-B1 PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN ICAGEN INC (US) 2010-01-13 EP disclosed
US-20080064690-A1 PYRAZOLE-AMIDES AND -SULFONAMIDES ICAGEN, INC. (US) 2008-03-13 US disclosed
US-7223782-B2 Pyrazole-amides and -sulfonamides ICAGEN, INC. (US) 2007-05-29 US disclosed
US-20050049237-A1 Pyrazole-amides and -sulfonamides ICAGEN, INC. (US) 2005-03-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080064690-A1 PYRAZOLE-AMIDES AND -SULFONAMIDES SCN3A, TRPV3, HCN3 KMT2A 2659/4885MEN1 4543/4885NPC1 3322/4885
US-20050049237-A1 Pyrazole-amides and -sulfonamides SCN3A, TRPV3, HCN3 KMT2A 2659/4885MEN1 4543/4885NPC1 3322/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.